Abstract
Background
We investigated evolocumab’s real-world effectiveness and safety on a background of statin therapy in the acute phase of ischemic stroke (IS) patients with a very high-risk of atherosclerotic cardiovascular disease (ASCVD).
Methods
A real-world, single-center, retrospective study was conducted in the neurology department at Tianjin Huanhu Hospital in China. Patients were divided into two groups: evolocumab treatment (140 mg every two weeks) or the standard of care (SOC) group. The primary efficacy outcome of the study was the achievement of a targeted lipid control rate and the incidence of major adverse cardiovascular events (MACE) by the end of the follow-up. MACE was defined as a composite of various cardiovascular events, cerebrovascular events such as stroke or TIA, and event-related deaths. Propensity score matching (PSM) analysis was utilized to account for confounding factors between groups. Survival analyses were performed using the Kaplan-Meier method and COX regression modeling.
Results
1080 AIS patients with very high-risk ASCVD were recruited. After PSM, there were 528 individuals, with 206 in the evolocumab group and 322 in the SOC group. At 12 months of follow-up, the proportion of LDL-C < 1.4mmol/L and ≥ 50% reduction was 44.91% in the evolocumab group, compared with only 3.12% of SOC-treated patients (p < 0.01). The median follow-up time for clinical events was 15 months. The evolocumab group was associated with a lower risk of cerebrovascular events compared to the SOC group (HR, 0.45; 95% CI, 0.23–0.89; p = 0.02).
Conclusions
This real-world study suggested that evolocumab on a background of statin reduced the LDL-C levels significantly and lowered the incidence of recurrent cerebrovascular events in the very high-risk ASCVD patients with AIS in China.
Similar content being viewed by others
Data availability
The dataset used and analyzed during the current study is available from the corresponding author on reasonable request.
Abbreviations
- IS:
-
Ischemic Stroke
- ASCVD:
-
Atherosclerotic Cardiovascular Disease
- SOC:
-
Standard of Care
- MACE:
-
Major Adverse Cardiovascular Events
- PSM:
-
Propensity Score Matching
- AIS:
-
Acute Ischemic Stroke
- RCTs:
-
Randomized controlled trials
- TIA:
-
Transient ischemic attacks
- PCSK9:
-
Proprotein Convertase Subtilisinkexin type 9
- ACS:
-
Acute Coronary Syndrome
- MI:
-
Myocardial Infarction
- LDL-C:
-
Low-Density Lipoprotein Cholesterol
- TC:
-
Total cholesterol
- TG:
-
Triglycerides
- HDL-C:
-
High-density Lipoprotein Cholesterol
- ApoA1:
-
Apolipoprotein A1
- ApoB:
-
Apolipoprotein B
- SAEs:
-
Serious Adverse Events
- mRS:
-
Modified Rankin Scale
- PAD:
-
Peripheral Artery Disease
- DM:
-
Diabetes Mellitus
- NIHSS:
-
National Institutes of Health Stroke Scale
- HR:
-
Hazard Ratios
- CHD:
-
Coronary Heart Disease
References
Wang YJ, Li ZX, Gu HQ, Zhai Y, Jiang Y, Zhao XQ et al (2020) China Stroke statistics 2019: a Report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and non-communicable Disease Control and Prevention. Stroke and Vascular Neurology 5(3):211–239. Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborationshttps://doi.org/10.1136/svn-2020-000457
Sirimarco G, Lavallee PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C et al (2013) Overlap of Diseases underlying ischemic Stroke: the ASCOD phenotyping. Stroke 44(9):2427–2433. https://doi.org/10.1161/STROKEAHA.113.001363
Lavallée PC, Charles H, Albers GW, Caplan LR, Donnan GA, Ferro JM et al (2023) Effect of Atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic Attack or minor ischaemic Stroke: an international prospective cohort study. Lancet Neurol 22(4):320–329. https://doi.org/10.1016/s1474-4422(23)00067-4
Vergallo R, Crea F (2020) Atherosclerotic Plaque Healing. N Engl J Med 383(9):846–857. https://doi.org/10.1056/NEJMra2000317
Amarenco P, Bogousslavsky J (2006) and, High-dose atorvastatin after Stroke or transient ischemic Attack. J Vasc Surg.
Ntaios G, Milionis H (2019) Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic Stroke. Int J Stroke: Official J Int Stroke Soc 14(5):476–482. https://doi.org/10.1177/1747493019851283
Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y et al (2020) A comparison of two LDL cholesterol targets after ischemic Stroke. N Engl J Med 382(1):9. https://doi.org/10.1056/NEJMoa1910355
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al (2015) Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med 372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trialCholesterol Treatment trialists’ (CTT) CollaborationLancet20103761670168110.1016/S0140-6736(10)61350-5298822421067804. Lancet 376(9753):1670–1681
HPS2-THRIVE randomized (2013) Placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34(17):1279–1291. https://doi.org/10.1093/eurheartj/eht055
Shui-ping, Zhao Bi-lian (2014) Yu, Dao-quan, Peng, The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the \{CHILLAS\} trial. Atherosclerosis.
Schuster S, Rubil S, Endres M, Princen HMG, Boeckel JN, Winter K et al Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. Entific Reports
A KCK, A SW BGP, C CM (2019) Evolocumab for early reduction of LDLCholesterol levels in patients with Acute Coronary syndromes (EVOPACS). J Am Coll Cardiol 74(20):2452–2462
[Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients] (2020) Zhonghua Xin xue guan bing za zhi. 48(4):280–286. https://doi.org/10.3760/cma.j.cn112148-20200121-00036
Wu Z, Wu D, Jiang J, Chen A, Zheng DD, Li J et al (2020) Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study. BMJ Open 10(5):e034585. https://doi.org/10.1136/bmjopen-2019-034585
Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE et al (2020) Evolocumab in Pediatric heterozygous familial hypercholesterolemia. N Engl J Med 383(14):1317–1327. https://doi.org/10.1056/NEJMoa2019910
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al (2017) Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. :1713
Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML et al (2019) Efficacy and safety of evolocumab in individuals with type 2 Diabetes Mellitus: primary results of the randomised controlled BANTING study. Diabetologia.
Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA et al (2020) Stroke Prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin type 9) inhibitor Evolocumab added to statin in high-risk patients with stable Atherosclerosis. Stroke 51(5):1546–1554. https://doi.org/10.1161/STROKEAHA.119.027759
Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y et al (2018) Corrigendum to Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163,641 adults [Int. J. Cardiol. 260 (2018) 196–203]. Int J Cardiol 267:218. https://doi.org/10.1016/j.ijcard.2018.04.100
Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, Rhabdomyolysis, and Cancer: insights from large randomized statin trials. Journal of the American College of Cardiology
Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF et al (2017) Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology 88(4):379–385. https://doi.org/10.1212/wnl.0000000000003534
Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J et al (2008) Atorvastatin reduces the risk of cardiovascular events in patients with carotid Atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 39(12):3297–3302. https://doi.org/10.1161/strokeaha.108.516450
Lau KK, Chua BJ, Ng A, Leung IY, Wong YK, Chan AH et al (2021) Low-density lipoprotein cholesterol and risk of recurrent vascular events in Chinese patients with ischemic Stroke with and without significant Atherosclerosis. J Am Heart Assoc 10(16):e021855. https://doi.org/10.1161/jaha.121.021855
Wu L, Kong Q, Huang H, Xu S, Qu W, Zhang P et al (2023) Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: a high-resolution MRI study. Front Aging Neurosci 15:1127534. https://doi.org/10.3389/fnagi.2023.1127534
Ameriso SF, Amarenco P, Pearce LA, Perera KS, Ntaios G, Lang W et al (2020) Intracranial and systemic Atherosclerosis in the NAVIGATE ESUS trial: recurrent Stroke risk and response to antithrombotic therapy. J Stroke Cerebrovasc Diseases: Official J Natl Stroke Association 29(8):104936. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104936
Ntaios G, Perlepe K, Sirimarco G, Strambo D, Eskandari A, Karagkiozi E et al (2019) Carotid plaques and detection of atrial fibrillation in embolic Stroke of undetermined source. Neurology 92(23):e2644–e52. https://doi.org/10.1212/WNL.0000000000007611
Ntaios G, Wintermark M, Michel P (2021) Supracardiac Atherosclerosis in embolic Stroke of undetermined source: the underestimated source. Eur Heart J 42(18):1789–1796. https://doi.org/10.1093/eurheartj/ehaa218
Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE et al (2019) Efficacy and safety of Rivaroxaban Versus aspirin in Embolic Stroke of undetermined source and Carotid Atherosclerosis. Stroke 50(9):2477–2485. https://doi.org/10.1161/STROKEAHA.119.025168
Oesterle A, Liao JK (2019) The Pleiotropic effects of statins - from coronary artery Disease and Stroke to Atrial Fibrillation and ventricular tachyarrhythmia. Curr Vasc Pharmacol 17(3):222–232. https://doi.org/10.2174/1570161116666180817155058
Yousuf A, McVey DG, Ye S (2022) Relationship between Red Meat Metabolite Trimethylamine N-oxide and Cardiovascular Disease. Heart and Mind 6(1):3–9. https://doi.org/10.4103/hm.hm_8_21
Ntaios G, Papavasileiou V, Makaritsis K, Milionis H, Manios E, Michel P et al (2014) Statin treatment is associated with improved prognosis in patients with AF-related Stroke. Int J Cardiol 177(1):129–133. https://doi.org/10.1016/j.ijcard.2014.09.031
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al (2018) AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology. 2018
François M, Colin B, Catapano AL, Koskinas KC, Manuela C, Lina B et al (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (1):1
Sagris D, Ntaios G, Georgiopoulos G, Kakaletsis N, Elisaf M, Katsiki N et al (2020) Recommendations for lipid modification in patients with ischemic Stroke or transient ischemic Attack: a clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. Int J Stroke: Official J Int Stroke Soc 1747493020971970. https://doi.org/10.1177/1747493020971970
Hlatky MA (2019) A pound of Prevention? Assessing the value of new cholesterol-lowering Drugs. Annals of Internal Medicine
Acknowledgements
We express our gratitude to Dr. Yan Xu of the Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, whose invaluable assistance in statistical analysis has greatly enriched our research endeavors.
Funding
This work was supported by Tianjin Key Medical Discipline (Specialty) Construction Project (No. TJYXZDXK-052B) and Tianjin Health Commission Science and Technology Projects (TJWJ2021QN061).
Author information
Authors and Affiliations
Contributions
Conception and organization of the study: Ting Zhang, Yajing Zhang and Wei Yue.
Design and execution of the statistical analysis: Yajing Zhang and Ting Zhang.
Preparing the first draft: Ting Zhang.
Data collection and analysis, revision of the manuscript for intellectual content: Yun Yang, Haibing Liao, Xun Li, Ran Liu Xueqing Liu and Liqin Yang.
All authors have approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The Institutional Ethical Committee of the Tianjin Huanhu Hospital approved the study protocol with an exception to the requirement of written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors have no competing interests to declare.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhang, T., Zhang, Y., Yang, Y. et al. Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke. J Thromb Thrombolysis 57, 302–311 (2024). https://doi.org/10.1007/s11239-023-02925-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-023-02925-4